In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $8.81.
Higgins covers the Healthcare sector, focusing on stocks such as Ovid Therapeutics, Achieve Life Sciences, and Palatin Technologies. According to TipRanks, Higgins has an average return of 2.5% and a 32.39% success rate on recommended stocks.
Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $20.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.88 and a one-year low of $2.00. Currently, Achieve Life Sciences has an average volume of 130.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- ACHV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
- Achieve Life Sciences announces Phase 2 ORCA-V1 trial results
- Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
- Achieve Life Sciences announces board refresh
